Abstract:Ensuring the safety and efficacy of chemical compounds is crucial in small-molecule drug development. In the later stages of drug development, toxic compounds pose a significant challenge, losing valuable resources and time. Early and accurate prediction of compound toxicity using deep learning models offers a promising solution to mitigate these risks during drug discovery. In this study, we present the development of several deep-learning models aimed at evaluating different types of compound toxicity, including acute toxicity, carcinogenicity, hERG_cardiotoxicity (the human ether-a-go-go related gene caused cardiotoxicity), hepatotoxicity, and mutagenicity. To address the inherent variations in data size, label type, and distribution across different types of toxicity, we employed diverse training strategies. Our first approach involved utilizing a graph convolutional network (GCN) regression model to predict acute toxicity, which achieved notable performance with Pearson R 0.76, 0.74, and 0.65 for intraperitoneal, intravenous, and oral administration routes, respectively. Furthermore, we trained multiple GCN binary classification models, each tailored to a specific type of toxicity. These models exhibited high area under the curve (AUC) scores, with an impressive AUC of 0.69, 0.77, 0.88, and 0.79 for predicting carcinogenicity, hERG_cardiotoxicity, mutagenicity, and hepatotoxicity, respectively. Additionally, we have used the approved drug dataset to determine the appropriate threshold value for the prediction score in model usage. We integrated these models into a virtual screening pipeline to assess their effectiveness in identifying potential low-toxicity drug candidates. Our findings indicate that this deep learning approach has the potential to significantly reduce the cost and risk associated with drug development by expediting the selection of compounds with low toxicity profiles. Therefore, the models developed in this study hold promise as critical tools for early drug candidate screening and selection.

Exploring Low-Toxicity Chemical Space with Deep Learning for Molecular Generation

Advances in Deep Learning-Based 3D Molecular Generative Models

A deep learning based multi-model approach for predicting drug-like chemical compound's toxicity

Latent Chemical Space Searching for Plug-in Multi-objective Molecule Generation

ChemistGA: A Chemical Synthesizable Accessible Molecular Generation Algorithm for Real-World Drug Discovery

Using Support Vector Regression Coupled with the Genetic Algorithm for Predicting Acute Toxicity to the Fathead Minnow

Molecular substructure tree generative model for de novo drug design

CELLS: Cost-Effective Evolution in Latent Space for Goal-Directed Molecular Generation.

3D-SMGE: a pipeline for scaffold-based molecular generation and evaluation

VGAE-MCTS: A New Molecular Generative Model Combining the Variational Graph Auto-Encoder and Monte Carlo Tree Search

Generative chemistry: drug discovery with deep learning generative models

Molecular generation strategy and optimization based on A2C reinforcement learning in de novo drug design

Human-level molecular optimization driven by mol-gene evolution

Genetic Algorithm-Based Receptor Ligand: A Genetic Algorithm-Guided Generative Model to Boost the Novelty and Drug-Likeness of Molecules in a Sampling Chemical Space.

Deep active learning with high structural discriminability for molecular mutagenicity prediction

De novo drug design by iterative multiobjective deep reinforcement learning with graph-based molecular quality assessment

Diffusing on Two Levels and Optimizing for Multiple Properties: A Novel Approach to Generating Molecules with Desirable Properties

Deep Generative Models in De Novo Drug Molecule Generation

Diversity oriented Deep Reinforcement Learning for targeted molecule generation

Towards Exploring Large Molecular Space: an Efficient Chemical Genetic Algorithm.

Deep Generation Model Guided by the Docking Score for Active Molecular Design